Brokerage : Kiwoom Securities
Analyst : Hyemin Huh
Investment Rating : BUY (Maintained)
Target Price : KRW 2,100,000 (Maintained)
Core Momentum : Solid Q1 earnings driven by deferred Q4 revenue recognition, paired with uncertainty resolution via labor negotiations, order pipeline expansion, Plant 6 groundbreaking clarity, and Q3 Rockville revenue recognition.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price KRW 2,100,000 (Maintained) (Closing price as of April 1, 2026: KRW 1,572,000)
- Market Data: KOSPI Index (4/1) 5,478.70pt / Market Cap KRW 72.77 Trillion / Shares Outstanding 46,291,000 / Foreign Ownership 12.7% / Dividend Yield (2026E) 0.0% / Major Shareholders: Samsung C&T and 5 affiliates 74.3%
- Annual Financial Forecast (Kiwoom Securities Estimates):
- 2026F: Revenue KRW 5.48 Trillion (+20.2% YoY), Operating Profit KRW 2.47 Trillion (+19.7% YoY), OPM 45.2%, EBITDA KRW 3.05 Trillion, Pre-tax Profit KRW 2.56 Trillion, Net Profit (Controlling) KRW 1.95 Trillion, EPS KRW 42,155 (+78.5% YoY), PER 37.3x, PBR 7.77x, ROE 23.3%, EV/EBITDA 23.0x, Net Debt Ratio -27.0%
- 2027F: Revenue KRW 5.95 Trillion, Operating Profit KRW 2.70 Trillion, OPM 45.4%, EBITDA KRW 3.21 Trillion, Pre-tax Profit KRW 2.86 Trillion, Net Profit (Controlling) KRW 2.18 Trillion, EPS KRW 47,107, PER 33.4x, PBR 6.31x, ROE 20.9%, EV/EBITDA 21.1x, Net Debt Ratio -42.7%
🚀 2. [Market Opportunities & Business Outlook]
- Q1 2026 Earnings Preview:
- Consolidated revenue is projected at KRW 1.28 Trillion (+28% YoY, flat QoQ) and operating profit at KRW 581.3 Billion (+35% YoY, +10% QoQ, OPM 45%), slightly exceeding market consensus (Revenue KRW 1.25 Trillion, OP KRW 569.7 Billion).
- Recognition of deferred production batches from Q4 2025 is expected to drive higher-than-typical Q1 revenue contribution, with average Q1 FX tracking at 1,465.16 KRW/USD (+1% QoQ, +1% YoY).
- Trade Policy Environment & Plant 6 Roadmap:
- Clear timelines for Plant 6 groundbreaking are anticipated once regulatory visibility regarding the US Section 232 investigation and pharmaceutical tariffs is established.
- Indirect market impacts from Most Favored Nation (MFN) executive orders leading pharma clients to postpone product launches or withdraw products in Europe require continuous tracking.
- Commercial production from the Rockville facility (acquired late March) will commence recognition in Q3 financials.
- Risk Factors & Operational Scheduling:
- Potential retroactive wage adjustments from ongoing union negotiations are expected to be recognized in Q2 (currently excluded from baseline estimates pending final settlement).
- Plant 1 routine maintenance is scheduled for Q4 2026, but the actual revenue impact will fall into Q1 2027, presenting zero disruption to full-year 2026 numbers.
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics as an industry-leading CDMO demonstrating solid earnings resilience anchored by high profitability (OPM ~45%) and deferred revenue recognition, positioned for valuation re-rating once near-term overhangs around labor discussions and trade policy clarity are resolved. The overarching perspective prioritizes the structural growth unlocked by clarifying the Plant 6 construction roadmap, recognizing Rockville revenues in Q3, and securing subsequent global commercial contracts over transient macro and regulatory wait-and-see sentiment.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the financial impact of labor settlement terms in Q2, formal announcements regarding the Plant 6 groundbreaking schedule following tariff clarity, commercial top-line contributions from the Rockville site in Q3, and subsequent disclosures of major new CDMO contracts. These developments can be verified through future quarterly earnings releases, official company IR presentations, and regulatory filings on DART/KRX.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
